 |
Graft versus tumor and donor lymphocyte infusions |
Adoptive Immunotherapy |
Shimon Slavin, IL |
|
NK cell activation and tumor recognition |
Adoptive Immunotherapy |
Hans-Gustaf Ljunggren, SE |
|
Prospects for adoptive NK cell therapy of human cancer |
Adoptive Immunotherapy |
Karl Johan Malmberg, SE |
|
HER-2neu vaccines for breast, ovarian and prostate cancers |
Antibodies |
George E. Peoples, US |
|
Individual idiotype vaccines in hematological malignancies |
Antibodies |
Hakan Mellstedt, SE |
|
Anti-angiogenic agents: the interface between the immune system and the tumor |
Cancer and inflammation |
Arjan W. Griffioen, NL |
|
The inflammatory tumour microenvironment and its impact on cancer development. |
Cancer and inflammation |
Karin de Visser, NL |
|
Tumor induced immune suppression: role of oxidative stress |
Cancer and inflammation |
Rolf Kiessling, SE |
|
Cancer immunotherapy: how have we got to where we are now? |
Keynote Lecture |
John Wagstaff, GB |
|
Combining chemotherapy with immunotherapy |
T cell immunity versus tolerance |
Dmitry Gabrilovich, US |
|
Combining chemotherapy with immunotherapy |
T cell immunity versus tolerance |
Dmitry Gabrilovich, US |
|
Combining chemotherapy with immunotherapy |
T cell immunity versus tolerance |
Dmitry Gabrilovich, US |
|
Combining chemotherapy with immunotherapy |
T cell immunity versus tolerance |
Dmitry Gabrilovich, US |
|
Measuring T cell responses |
T cell immunity versus tolerance |
Pedro Romero, CH |
|
Adjuvants |
Vaccines I |
Hyam I. Levitsky, US |
|
Dendritic cell vaccines |
Vaccines II |
Carl Figdor, NL |
|
Old problems, new directions |
Vaccines II |
Eli Gilboa, US |
|
Viral and vector vaccines |
Vaccines II |
Joerg Schneider, US |
|
Whole cell vaccines |
Vaccines II |
Rik Scheper, NL |
BACK TO TOP
PRINT THIS PAGE